Charles River Laboratories International (NYSE:CRL) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Charles River Laboratories International (NYSE:CRL) had its target price increased by investment analysts at JPMorgan Chase & Co. from $165.00 to $190.00 in a research note issued on Monday,Benzinga reports. The brokerage currently has a “neutral” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s price objective suggests a potential downside of 3.69% from the company’s current price.

Several other research firms have also commented on CRL. William Blair upgraded shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research report on Monday, October 6th. Barclays reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Charles River Laboratories International in a report on Monday. Baird R W raised Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 6th. Mizuho raised their price objective on Charles River Laboratories International from $155.00 to $174.00 and gave the company a “neutral” rating in a research note on Friday, October 17th. Finally, TD Cowen dropped their price objective on shares of Charles River Laboratories International from $205.00 to $197.00 and set a “buy” rating for the company in a research note on Monday, November 10th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $194.07.

Charles River Laboratories International Price Performance

Shares of CRL stock traded up $4.25 during trading hours on Monday, hitting $197.28. The stock had a trading volume of 359,406 shares, compared to its average volume of 1,167,117. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.37 and a quick ratio of 1.10. The stock has a market capitalization of $9.71 billion, a price-to-earnings ratio of -126.37, a PEG ratio of 6.82 and a beta of 1.63. Charles River Laboratories International has a one year low of $91.86 and a one year high of $200.58. The stock’s 50-day moving average price is $177.40 and its two-hundred day moving average price is $163.66.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, beating the consensus estimate of $2.32 by $0.11. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.The firm’s revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter last year, the business posted $2.59 EPS. Equities analysts forecast that Charles River Laboratories International will post 9.36 EPS for the current year.

Institutional Trading of Charles River Laboratories International

Large investors have recently modified their holdings of the company. Brooklyn Investment Group grew its holdings in Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock worth $27,000 after acquiring an additional 86 shares in the last quarter. Cromwell Holdings LLC lifted its position in shares of Charles River Laboratories International by 542.9% in the 2nd quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock worth $27,000 after purchasing an additional 152 shares during the period. Neo Ivy Capital Management bought a new position in shares of Charles River Laboratories International during the second quarter valued at approximately $29,000. Rothschild Investment LLC increased its holdings in Charles River Laboratories International by 82.4% during the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after buying an additional 84 shares during the period. Finally, Atlantic Union Bankshares Corp bought a new position in Charles River Laboratories International in the third quarter worth approximately $31,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).